Albumin in Acute Ischemic Stroke Trial "ALIAS"


Phase 3 Results N/A

Summary of Purpose

The goal of the trial is to determine whether human albumin, administered within 5 hours of symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke. Trial Stopped: Recruitment halted by DSMB following interim analysis.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 14 November 2012.

1 Jun 2006 14 Sep 2005 1 Feb 2013 1 Jun 2014 1 Nov 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment